1. De Young L, Bella A, Gan BS, Brock G. The pathogenesis of Peyronie's disease: a state of altered wound healing. J Sex Med 2005; 3 (Suppl 1):24 (Abstract #34).
2. Brock G, Bella A, Gan BS, De Young L. Use of SELDI to determine whether Peyronie's disease protein expression can predict progression. J Sex Med 2005; 3 (Suppl 1):18 (Abstract #15).
3. Mazo F, Ivanchenko L, Maufagued M. New in the pathogenesis of Peyronie's disease. J Sex Med 2005; 3 (Suppl 1):44 (Abstract #96).
4. Ferrini M, Lovanecz I, Nolazco G, Rajfer J, Gonazlez-Kadavid N. Long-term treatment with vardenafil reduces the development of the fibrotic plaque in a rat model of Pyeronie's disease. J Sex Med 2005; 3 (Suppl 1):27 (Abstract #43).
5. Davila HH, Garcia JE, Broderick G, Carrion RE. Demographic characteristics and the prevalence of comorbid conditions in patients with Peyronie's disease. J Sex Med 2005; 2 (Suppl 1):22 (Abstract #28).
6. Kendirci M, Trost L, Sikka SC, Hellstrom WJG. Diabetes mellitus is a risk factor for increase severity of Peyronie's disease: a comparative clinical study. J Sex Med 2005; 3 (Suppl 1):36-7 (Abstract #72).
7. Obebshalom M, Guhring P, Mulhall JP. Measurement of penile curvature in Peyronie's disease patients: Correlation between intracavernosal injection, vacuum device and at-home photography. J Sex Med 2005; 3 (Suppl 1):50 (Abstract #116).
8. Greenfield JM, Shah SJ< Levine LA> Verapamil versus saline in electromotive drug administration (EMDA) for Peyronie's disease: A double blind, placebo-controlled trial. J Sex Med 2005; 3 (Suppl 1):30-1 (Abstract #53).

Please log-in or register in order to submit comments.

Powered by AkoComment!